RWS of Inetetamab HER2 Positive Advanced Breast Cancer

HER2-positive Advanced Breast Cancer Clinical Trial

Official title:
Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer

Status Not yet recruiting

Clinical Trial Summary

This non-Interventional study will describe and analyze the clinical use of Inetetamab in clinical practice in the treatment of HER2 positive advanced breast cancer in the real world.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
HER2-positive Advanced Breast Cancer

Clinical Trial Details

NCT number	NCT04963608
Study type	Observational
Source	Shandong Cancer Hospital and Institute
Contact	Zhiyong yu
Phone	86-13355312277
Email	drzhiyongyu@aliyun.com
Status	Not yet recruiting
Phase
Start date	July 2021
Completion date	December 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05856383` - Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
Not yet recruiting	`NCT05901935` - DP303c in Patients With HER2-positive Advanced Breast Cancer	Phase 3
Active, not recruiting	`NCT04185649` - The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer	Phase 3
Completed	`NCT04903652` - Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer	Phase 2